Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Assets (2016 - 2025)

Ascendis Pharma A's Assets history spans 7 years, with the latest figure at $888.3 million for Q4 2023.

  • For Q4 2023, Assets fell 20.1% year-over-year to $888.3 million; the TTM value through Dec 2023 reached $888.3 million, down 20.1%, while the annual FY2023 figure was $893.1 million, 22.24% down from the prior year.
  • Assets for Q4 2023 was $888.3 million at Ascendis Pharma A, down from $1.1 billion in the prior quarter.
  • Across five years, Assets topped out at $1.2 billion in Q4 2021 and bottomed at $749.1 million in Q4 2019.
  • The 4-year median for Assets is $1.0 billion (2023), against an average of $997.6 million.
  • The largest annual shift saw Assets surged 105.75% in 2019 before it dropped 20.1% in 2023.
  • A 4-year view of Assets shows it stood at $749.1 million in 2019, then surged by 65.69% to $1.2 billion in 2021, then dropped by 10.42% to $1.1 billion in 2022, then decreased by 20.1% to $888.3 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Assets are $888.3 million (Q4 2023), $1.1 billion (Q4 2022), and $1.2 billion (Q4 2021).